Summary of Clinical Trial Results
Study Overview
Patients with diabetes mellitus were treated with either Orsiro stent (O-SES) or Nobori stent (N-BES) in a 5-year trial.
Key Findings
– Patients with diabetes had higher risk of target lesion failure (TLF) compared to those without diabetes.
– Among diabetic patients, there was no significant difference in TLF between O-SES and N-BES after 5 years.
– Cardiac death, myocardial infarction, revascularization, and stent thrombosis did not differ between the two groups.
Practical Solutions and Value
Diabetic patients treated with biodegradable polymer stents showed similar 5-year outcomes with both O-SES and N-BES.
Utilizing AI-driven platforms like DocSym can help clinicians access standardized clinical knowledge easily.
Mobile apps can streamline operations, support patient care, and enable expansion of digital services in healthcare.
AI implementation in clinics can enhance workflows, improve patient outcomes, and reduce paperwork.
For more information on how we can assist, visit aidevmd.com.
